Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area.

"BE is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd, and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company and Lundbeck Pharma A/S. FKK has served on scientific advisory panels and/or been part of speaker’s bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi, ShouTi, Zealand Pharma and Zucara. The other authors declare no conflict of interests."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article. Grimur Høgnason Mohr received salary from a grant from Independent Research Fund Denmark (Case number 2096-00099B) during the reviewing process from February 2023."